An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Axonics, Inc. (NASDAQ: AXNX) has announced the granting of eight patents and the allowance of four patent applications related to its sacral neuromodulation technology over the past year. These patents cover innovations such as the Axonics external trial system and implantable neurostimulator. CEO Raymond W. Cohen emphasized the company’s commitment to addressing the needs of adults with incontinence. Axonics' product portfolio includes clinically proven therapies for overactive bladder and fecal incontinence, with established reimbursement coverage in the U.S. and Europe.
Positive
Eight patents granted and four applications allowed related to sacral neuromodulation technology, indicating strong innovation.
Strong product portfolio for treating overactive bladder and fecal incontinence, addressing significant market demand.
Established reimbursement coverage in the U.S. and most European countries.
Negative
None.
IRVINE, Calif.--(BUSINESS WIRE)--
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that in the last twelve months, the United States Patent and Trademark Office has granted eight patents and allowed four patent applications related to the company’s sacral neuromodulation technology.
The patents and allowed applications are part of Axonics’ patent portfolio and represents technology internally developed by the company covering a range of subject matter that includes the Axonics external trial system, tined lead, implantable neurostimulator, clinician programmer, wireless charging system and patient remote control.
The granted U.S. patents are numbered: 11,083,903; 11,110,283; 11,116,985; 11,123,569; 11,213,675; 11,260,236; 11,389,659; and D952,859. The allowed U.S. patent applications are numbered: 16/547,324; 16/871,738; 16/913,532; and 16/882,295.
“Axonics is committed to developing best-in-class technology to serve the unmet needs of the millions of adults suffering from incontinence. The volume, subject matter diversity, and breadth of these patents demonstrate the investment in innovation that Axonics continues to make in sacral neuromodulation technology,” said Raymond W. Cohen, chief executive officer.
About Axonics
Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.
Axonics sacral neuromodulation (SNM) systems provide adults suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 29 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.
In the last twelve months, Axonics received eight patents and had four patent applications allowed related to their sacral neuromodulation technology.
How does the new patent portfolio impact Axonics (AXNX)?
The new patent portfolio enhances Axonics' competitive edge in the treatment of bladder and bowel dysfunction, showcasing its commitment to innovation.
What are the applications covered by Axonics' patents?
The patents cover various technologies including the external trial system, tined lead, implantable neurostimulator, clinician programmer, wireless charging system, and patient remote control.
Does Axonics (AXNX) have reimbursement coverage?
Yes, Axonics has well-established reimbursement coverage in the U.S. and is a covered service in most European countries.
What is the focus of Axonics' technology?
Axonics focuses on developing products specifically for the treatment of bladder and bowel dysfunction.
